Ausgabe 6/2023
Inhalt (12 Artikel)
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy
Lars Børty, Rasmus F. Brøndum, Heidi S. Christensen, Charles Vesteghem, Marianne Severinsen, Søren P. Johnsen, Lars H. Ehlers, Ursula Falkmer, Laurids Ø. Poulsen, Martin Bøgsted
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France
Manon Belhassen, Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse, Nicolas Danchin
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study
Tonya Moen Hansen, Knut Stavem, Kim Rand
Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients
Chen-Wei Pan, Jun-Yi He, Yan-Bo Zhu, Chun-Hua Zhao, Nan Luo, Pei Wang
The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
Adie Viljoen, Barrie Chubb, Samuel J. P. Malkin, Sasha Berry, Barnaby Hunt, Stephen C. Bain
Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries
Xiao Li, Joke Bilcke, Alike W. van der Velden, Robin Bruyndonckx, Samuel Coenen, Emily Bongard, Muirrean de Paor, Slawomir Chlabicz, Maciek Godycki-Cwirko, Nick Francis, Rune Aabenhus, Heiner C. Bucher, Annelies Colliers, An De Sutter, Ana Garcia-Sangenis, Dominik Glinz, Nicolay J. Harbin, Katarzyna Kosiek, Morten Lindbæk, Christos Lionis, Carl Llor, Réka Mikó-Pauer, Ruta Radzeviciene Jurgute, Bohumil Seifert, Pär-Daniel Sundvall, Pia Touboul Lundgren, Nikolaos Tsakountakis, Theo J. Verheij, Herman Goossens, Christopher C. Butler, Philippe Beutels, Emily Bongard, Muirrean de Paor, Slawomir Chlabicz, Maciek Godycki-Cwirko, Nick Francis, Rune Aabenhus, Heiner C. Bucher, Annelies Colliers, An De Sutter, Ana Garcia-Sangenis, Dominik Glinz, Nicolay J. Harbin, Katarzyna Kosiek, Morten Lindbæk, Christos Lionis, Carl Llor, Réka Mikó-Pauer, Ruta Radzeviciene Jurgute, Bohumil Seifert, Pär-Daniel Sundvall, Pia Touboul Lundgren, Nikolaos Tsakountakis
Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand
Suzi Claflin, Julie A. Campbell, Richard Norman, Deborah F. Mason, Tomas Kalincik, Steve Simpson-Yap, Helmut Butzkueven, William M. Carroll, Andrew J. Palmer, C. Leigh Blizzard, Ingrid van der Mei, Glen J. Henson, Bruce V. Taylor
The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?
Ângela Jornada Ben, Johanna M. van Dongen, Mohamed El Alili, Martijn W. Heymans, Jos W. R. Twisk, Janet L. MacNeil-Vroomen, Maartje de Wit, Susan E. M. van Dijk, Teddy Oosterhuis, Judith E. Bosmans
Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks
Meg Perry-Duxbury, Sebastian Himmler, Job van Exel, Werner Brouwer
The application of discrete choice experiments eliciting young peoples’ preferences for healthcare: a systematic literature review
Galina Williams, Irina Kinchin
Does competition improve hospital performance: a DEA based evaluation from the Netherlands
Peter Dohmen, Martin van Ineveld, Aniek Markus, Liana van der Hagen, Joris van de Klundert